

Xiaoxiao Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6503073/publications.pdf>

Version: 2024-02-01

38
papers

513
citations

687220

13
h-index

752573

20
g-index

45
all docs

45
docs citations

45
times ranked

831
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. <i>International Journal of Cardiology</i> , 2017, 236, 432-437.	0.8	81
2	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	0.8	52
3	Serum IgE levels are associated with coronary artery disease severity. <i>Atherosclerosis</i> , 2016, 251, 355-360.	0.4	36
4	Oxidation and CaMKII-mediated Sarcoplasmic Reticulum Ca ²⁺ Leak Triggers Atrial Fibrillation in Aging. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 645-652.	0.8	24
5	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020, 11, 799-804.	0.8	24
6	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 111-118.	0.5	22
7	Oxidation of Ryanodine Receptors Promotes Ca ²⁺ Leakage and Contributes to Right Ventricular Dysfunction in Pulmonary Hypertension. <i>Hypertension</i> , 2021, 77, 59-71.	1.3	20
8	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 979-985.	1.0	19
9	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	0.8	19
10	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 488-492.	0.8	17
11	Echocardiographic Characteristics of Intravenous Leiomyomatosis with Intracardiac Extension: A Single-Institution Experience. <i>Echocardiography</i> , 2011, 28, 934-940.	0.3	16
12	Role of IgE-FcγR1 in Pathological Cardiac Remodeling and Dysfunction. <i>Circulation</i> , 2021, 143, 1014-1030.	1.6	16
13	Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 152, 52-68.	0.9	15
14	The role of immunoglobulin E and mast cells in hypertension. <i>Cardiovascular Research</i> , 2022, 118, 2985-2999.	1.8	15
15	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020, 11, 3047-3052.	0.8	13
16	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. <i>Frontiers in Medicine</i> , 2020, 7, 583944.	1.2	12
17	Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies. <i>Journal of the American Heart Association</i> , 2022, 11, e024449.	1.6	11
18	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020, 11, 475-480.	0.8	9
20	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. <i>Hypertension</i> , 2020, 76, 1161-1168.	1.3	8
21	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	0.8	8
22	Proteomic and Metabolomic Analyses of Right Ventricular Failure due to Pulmonary Arterial Hypertension. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
23	A Case of Novel Lamin A/C Mutation Manifesting as Atypical Progeroid Syndrome and Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1166.e29-1166.e31.	0.8	7
24	The Relationship of Serum Antigen-Specific and Total Immunoglobulin E with Adult Cardiovascular Diseases. <i>International Journal of Medical Sciences</i> , 2018, 15, 1098-1104.	1.1	7
25	Top 100 most-cited articles on echocardiography: A bibliometric analysis. <i>Echocardiography</i> , 2019, 36, 1540-1548.	0.3	6
26	A Novel Dystrophin Deletion Mutation in a Becker Muscular Dystrophy Patient With Early-Onset Dilated Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2014, 30, 956.e1-956.e3.	0.8	5
27	Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , 2018, 37, 2989-2998.	1.0	5
28	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020, 11, 829-834.	0.8	5
29	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020, 11, 1099-1104.	0.8	5
30	Ventricular arrhythmia predicts poor outcome in polymyositis/dermatomyositis with myocardial involvement. <i>Rheumatology</i> , 2021, 60, 3809-3816.	0.9	5
31	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 198-202.	0.8	2
32	SARS-CoV-2 leads to myocardial injury in rhesus macaque. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 338.	7.1	2
33	Giant aortic pseudoaneurysm fistulized into right atrium. <i>European Heart Journal</i> , 2012, 33, 1733-1733.	1.0	1
34	The octopus on a heart. <i>European Heart Journal</i> , 2019, 40, 635-635.	1.0	1
35	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020, 11, 2077-2086.	0.8	1
36	Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S26-S33.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Myocarditis in patients treated with anti-“programmed death-1/programmed death ligand 1 therapy.. Journal of Clinical Oncology, 2021, 39, e14579-e14579.	0.8	0
38	Predictive value of heart rate in patients with acute type A aortic dissection: a retrospective cohort study. BMJ Open, 2021, 11, e047221.	0.8	0